Toripalimab, identified chemically as compound 1924598-82-2, represents a modified monoclonal antibody engineered to engage PD-1, an immune checkpoint protein. Its mode of function involves blocking the interaction between programmed death-1 and its counterparts, specifically PD-L1 and PDL2, causing to the stimulation of T cells and subsequent canc